Johnson & Johnson Reports 2013 Fourth-Quarter and Full-Year Results:

2013 Fourth-Quarter Sales of $18.4 Billion increased 4.5%; EPS was $1.23

2013 Full-Year Sales of $71.3 Billion increased 6.1%; Full-Year EPS was $4.81

Excluding Special Items, 2013 Fourth-Quarter EPS was $1.24, an increase of 4.2%*

And 2013 Full-Year EPS was $5.52, an increase of 8.2%*

21 Jan, 2014, 07:45 ET from Johnson & Johnson

NEW BRUNSWICK, N.J., Jan. 21, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of $18.4 billion for the fourth quarter of 2013, an increase of 4.5% as compared to the fourth quarter of 2012. Operational results increased 6.3% and the negative impact of currency was 1.8%. Domestic sales increased 7.4%, while international sales increased 2.4%, reflecting operational growth of 5.6% and a negative currency impact of 3.2%. Worldwide sales for the full-year 2013 were $71.3 billion, an increase of 6.1% versus 2012. Operational sales increased 7.7% and the negative impact of currency was 1.6%.  Domestic sales increased 7.0%, while international sales increased 5.4%, reflecting operational growth of 8.2% and a negative currency impact of 2.8%. Sales for the full year included the acquisition of Synthes, Inc. which was completed in June 2012.  Excluding this impact, net of the divestiture of the DePuy trauma business, worldwide operational sales growth was 5.2%.

Net earnings** and diluted earnings per share for the fourth quarter of 2013 were $3.5 billion and $1.23, respectively. Fourth-quarter 2013 net earnings included after-tax special items of $42 million, primarily related to an increase in the litigation accrual, an in-process research and development charge, integration and transaction costs related to the acquisition of Synthes, Inc., and program costs associated with the DePuy ASRHip, offset by a tax benefit associated with Scios, Inc. Fourth-quarter 2012 net earnings reflect after-tax special items of $0.8 billion as detailed in the accompanying reconciliation of non-GAAP financial measures. Excluding these special items, net earnings for the quarter were $3.6 billion and diluted earnings per share were $1.24, representing increases of 5.5% and 4.2%, respectively, as compared to the same period in 2012.*

Net earnings** and diluted earnings per share for the full-year 2013 were $13.8 billion and $4.81, respectively.  Full-year net earnings reflect after-tax special items of $2.0 billion in 2013 and $3.5 billion in 2012 as detailed in the accompanying reconciliation of non-GAAP financial measures. Excluding these special items in both periods, net earnings for the full-year of 2013 were $15.9 billion and diluted earnings per share were $5.52, representing increases of 10.7% and 8.2%, respectively, as compared with the full year of 2012.*

"Johnson & Johnson delivered strong results in 2013 led by the outstanding performance in our Pharmaceutical business, the strength of key brands in our US OTC and other Consumer businesses and continued progress in integrating Synthes into our Medical Devices and Diagnostics business.  We also advanced our longer term growth drivers, bringing innovative solutions to the global healthcare market and executing with excellence", said Alex Gorsky, Chairman and Chief Executive Officer.  "I am proud of our exceptional Johnson & Johnson colleagues for their commitment to leading with purpose and advancing health and well-being for patients and consumers around the world."

The Company announced earnings guidance for full-year 2014 of $5.75 to $5.85 per share, which excludes the impact of special items.

Worldwide Consumer sales of $14.7 billion for the full-year 2013 represented an increase of 1.7% versus the prior year, consisting of an operational increase of 2.8% and a negative impact from currency of 1.1%. Domestic sales increased 2.3%; international sales increased 1.4%, which reflected an operational increase of 3.1% and a negative currency impact of 1.7%.

Positive contributors to operational results were U.S. sales of TYLENOL® and MOTRIN® analgesics; upper respiratory over-the-counter products; international sales of baby care products; sales of NEUTROGENA® and AVEENO® skin care products; and international sales of LISTERINE® oral care products .

Worldwide Pharmaceutical sales of $28.1 billion for the full-year 2013 represented an increase of 10.9% versus the prior year with an operational increase of 12.0% and a negative impact from currency of 1.1%. Domestic sales increased 12.3%; international sales increased 9.6%, which reflected an operational increase of 11.8% and a negative currency impact of 2.2%.

Primary contributors to operational sales growth were REMICADE® (infliximab) and SIMPONI® (golimumab), biologics approved for the treatment of a number of immune-mediated inflammatory diseases; STELARA® (ustekinumab), a biologic approved for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis; INVEGA® SUSTENNA®/XEPLION® (paliperidone palmitate), a once-monthly, long-acting, injectable atypical antipsychotic for the treatment of schizophrenia in adults;  PREZISTA® (darunavir), a treatment for HIV; DOXIL® (doxorubicin HCl liposome injection)/CAELYX® (pegylated liposomal doxorubicin hydrochloride), a medication to treat recurrent ovarian and other cancers; VELCADE® (bortezomib), a treatment for multiple myeloma; and sales of new products. 

The strong sales results of new products included ZYTIGA® (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer; XARELTO® (rivaroxaban), an oral anticoagulant; the combined sales of COMPLERA®/EVIPLERA® (emtricitabine /rilpivirine/tenofovir disoproxil fumarate) and EDURANT® (rilpivirine) for the treatment of HIV and INVOKANA® (canagliflozin) for the treatment of adults with type 2 diabetes.

Sales results were negatively impacted by loss of exclusivity for ACIPHEX®/ PARIET® (rabeprazole), a proton pump inhibitor for gastrointestinal disorders and CONCERTA® (methylphenidate HCI) for the treatment of attention deficit hyperactivity disorder.

During the quarter, the U.S. Food and Drug Administration (FDA) granted approval of OLYSIO (simeprevir) for combination treatment of chronic hepatitis C.  The FDA also approved IMBRUVICA (ibrutinib) to treat mantle cell lymphoma for patients who received at least one prior treatment. The European Commission approved INVOKANA® (canagliflozin) for the treatment of adults with type 2 diabetes.  In addition, SIRTURO® (bedaquiline) received a positive opinion from the European Committee for Medicinal Products for use as part of combination therapy to treat adults with pulmonary multi-drug resistant tuberculosis.

A Marketing Authorization Application was submitted to the European Medicines Agency (EMA) for ibrutinib for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma.  Also filed with the EMA, was a once-daily single tablet fixed-dose antiretroviral combination product containing darunavir, a protease inhibitor developed by Janssen-Cilag International NV marketed as PREZISTA®, with cobicistat, a pharmacokinetic boosting agent, developed by Gilead Sciences, Inc. for use in combination with other HIV medicines.

Worldwide Medical Devices and Diagnostics (MD&D) sales of $28.5 billion for the full-year 2013 represented an increase of 3.9% versus the prior year with an operational increase of 6.1% and a negative impact from currency of 2.2%. Domestic sales increased 3.5%.  International sales increased 4.2%, which reflected an operational increase of 8.3% and a negative currency impact of 4.1%. Sales included the impact of the acquisition of Synthes, Inc., net of the divestiture of the DePuy trauma business. Excluding this impact, worldwide MD&D operational sales growth was 0.1%.

Primary contributors to operational growth were sales from the acquisition of Synthes, Inc. and joint reconstruction products in the Orthopaedics business; Biosense Webster's electrophysiology products in the Cardiovascular Care business; the Vision Care business; as well as biosurgicals and international sales of energy products in the Specialty Surgery business.               

About Johnson & Johnson

Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 128,000 employees at more than 275 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

* Net earnings** and diluted earnings per share, excluding special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.  A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures is included in the financial schedules accompanying this press release and can be found in the Investor Relations section of the Company's website at www.investor.jnj.com.

** Net earnings and diluted earnings per share attributable to Johnson & Johnson.

Johnson & Johnson will conduct a meeting with investors to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com

Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm.  These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliation of non-GAAP financial measures, and sales of key products/franchises.  Additional information on Johnson & Johnson, including a pharmaceutical pipeline of selected compounds in late stage development can be found on the Company's website at www.investor.jnj.com.

NOTE TO INVESTORS

(This release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events.  If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson.  Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; significant adverse litigation or government action; impact of business combinations; financial distress and bankruptcies experienced by significant customers and suppliers; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; increased scrutiny of the health care industry by government agencies; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and sovereign risk; disruptions due to natural disasters; manufacturing difficulties or delays; complex global supply chains with increasing regulatory requirements; and product efficacy or safety concerns resulting in product recalls or regulatory action. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2012.  Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.investor.jnj.com or on request from Johnson & Johnson.   Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.)

 

Johnson & Johnson and Subsidiaries

Supplementary Sales Data

(Unaudited; Dollars in Millions)

FOURTH QUARTER

TWELVE MONTHS

Percent Change

Percent Change

2013

2012

Total

Operations

Currency

2013

2012

Total

Operations

Currency

Sales to customers by

segment of business

Consumer

    U.S.

$   1,263

1,203

5.0

%

5.0

-

$   5,162

5,046

2.3

%

2.3

-

    International

2,490

2,449

1.7

4.1

(2.4)

9,535

9,401

1.4

3.1

(1.7)

3,753

3,652

2.8

4.4

(1.6)

14,697

14,447

1.7

2.8

(1.1)

Pharmaceutical

    U.S.

3,551

3,013

17.9

17.9

-

13,948

12,421

12.3

12.3

-

    International

3,745

3,512

6.6

9.0

(2.4)

14,177

12,930

9.6

11.8

(2.2)

7,296

6,525

11.8

13.1

(1.3)

28,125

25,351

10.9

12.0

(1.1)

Med Devices & Diagnostics

    U.S.

3,200

3,244

(1.4)

(1.4)

-

12,800

12,363

3.5

3.5

-

    International

4,106

4,137

(0.7)

3.7

(4.4)

15,690

15,063

4.2

8.3

(4.1)

7,306

7,381

(1.0)

1.5

(2.5)

28,490

27,426

3.9

6.1

(2.2)

U.S.

8,014

7,460

7.4

7.4

-

31,910

29,830

7.0

7.0

-

International

10,341

10,098

2.4

5.6

(3.2)

39,402

37,394

5.4

8.2

(2.8)

Worldwide

$ 18,355

17,558

4.5

%

6.3

(1.8)

$ 71,312

67,224

6.1

%

7.7

(1.6)

 

Johnson & Johnson and Subsidiaries

Supplementary Sales Data

(Unaudited; Dollars in Millions)

FOURTH QUARTER

TWELVE MONTHS

Percent Change

Percent Change

2013

2012

Total

Operations

Currency

2013

2012

Total

Operations

Currency

Sales to customers by

geographic area

U.S.

$   8,014

7,460

7.4

%

7.4

-

$ 31,910

29,830

7.0

%

7.0

-

Europe

4,968

4,603

7.9

4.8

3.1

18,599

16,945

9.8

7.7

2.1

Western Hemisphere excluding U.S.

1,891

1,941

(2.6)

4.8

(7.4)

7,421

7,207

3.0

8.9

(5.9)

Asia-Pacific, Africa

3,482

3,554

(2.0)

7.0

(9.0)

13,382

13,242

1.1

8.6

(7.5)

International

10,341

10,098

2.4

5.6

(3.2)

39,402

37,394

5.4

8.2

(2.8)

Worldwide

$ 18,355

$ 17,558

4.5

%

6.3

(1.8)

$ 71,312

$ 67,224

6.1

%

7.7

(1.6)

 

Johnson & Johnson and Subsidiaries

Condensed Consolidated Statement of Earnings 

(Unaudited; in Millions Except Per Share Figures)

FOURTH QUARTER

2013

2012

Percent

Percent

Percent

Increase

Amount

to Sales

Amount

to Sales

(Decrease)

Sales to customers

$ 18,355

100.0

$ 17,558

100.0

4.5

Cost of products sold

5,955

32.5

6,003

34.2

(0.8)

Selling, marketing and administrative expenses

5,917

32.2

5,661

32.2

4.5

Research and development expense

2,411

13.1

2,331

13.3

3.4

In-process research and development

338

1.9

55

0.3

Interest (income) expense, net

116

0.6

89

0.5

Other (income) expense, net

868

4.7

319

1.8

Earnings before provision for taxes on income

2,750

15.0

3,100

17.7

(11.3)

Provision for/(Benefit from) taxes on income

(769)

(4.2)

533

3.1

Net earnings

3,519

19.2

2,567

14.6

37.1

Add: Net loss attributable to noncontrolling interest

-

-

-

-

Net earnings attributable to Johnson & Johnson

$   3,519

19.2

$   2,567

14.6

37.1

Net earnings per share attributable to Johnson & Johnson (Diluted)

$     1.23

$     0.91

35.2

Average shares outstanding (Diluted)

2,872.0

2,833.4

Effective tax rate

(28.0)

%

17.2

%

Adjusted earnings before provision for taxes and net earnings attributable to Johnson & Johnson (1)

Earnings before provision for taxes on income

$   3,909

21.3

$   4,115

23.4

(5.0)

Net earnings attributable to Johnson & Johnson

$   3,561

19.4

$   3,376

19.2

5.5

Net earnings per share attributable to Johnson & Johnson (Diluted)

$     1.24

$     1.19

4.2

Effective tax rate

8.9

%

18.0

%

(1) See Reconciliation of Non-GAAP Financial Measures.

 

Johnson & Johnson and Subsidiaries

Condensed Consolidated Statement of Earnings 

(Unaudited; in Millions Except Per Share Figures)

TWELVE MONTHS

2013

2012

Percent

Percent

Percent

Increase

Amount

to Sales

Amount

to Sales

(Decrease)

Sales to customers

$ 71,312

100.0

$ 67,224

100.0

6.1

Cost of products sold

22,342

31.3

21,658

32.2

3.2

Selling, marketing and administrative expenses

21,830

30.6

20,869

31.0

4.6

Research and development expense

8,183

11.5

7,665

11.4

6.8

In-process research and development

580

0.8

1,163

1.7

Interest (income) expense, net

408

0.6

468

0.7

Other (income) expense, net

2,498

3.5

1,626

2.5

Earnings before provision for taxes on income

15,471

21.7

13,775

20.5

12.3

Provision for taxes on income

1,640

2.3

3,261

4.9

(49.7)

Net earnings

13,831

19.4

10,514

15.6

31.5

Add: Net loss attributable to noncontrolling interest

-

-

339

0.5

Net earnings attributable to Johnson & Johnson

$ 13,831

19.4

$ 10,853

16.1

27.4

Net earnings per share attributable to Johnson & Johnson (Diluted)

$     4.81

$     3.86

24.6

Average shares outstanding (Diluted)

2,877.0

2,812.6

Effective tax rate

10.6

%

23.7

%

Adjusted earnings before provision for taxes and net earnings attributable to Johnson & Johnson (1)

Earnings before provision for taxes on income

$ 19,169

26.9

$ 18,214

27.1

5.2

Net earnings attributable to Johnson & Johnson

$ 15,876

22.3

$ 14,345

21.3

10.7

Net earnings per share attributable to Johnson & Johnson (Diluted)

$     5.52

$     5.10

8.2

Effective tax rate

17.2

%

21.2

%

(1) See Reconciliation of Non-GAAP Financial Measures.

 

Johnson & Johnson and Subsidiaries

Reconciliation of Non-GAAP Financial Measures

Fourth Quarter

% Incr. /

Twelve Months 

% Incr. /

(Dollars in Millions Except Per Share Data)

2013

2012

(Decr.)

2013

2012

(Decr.)

Earnings before provision for taxes on income - as reported

$ 2,750

3,100

(11.3)

%

$ 15,471

13,775

12.3

%

Litigation expenses

506

471

2,282

1,229

In-process research and development

338

55

580

1,163

Synthes integration/transaction costs and currency related

181

406

683

1,028

DePuy ASR™ Hip program

134

83

251

110

Intangible asset write-downs 

-

-

-

939

Other

-

-

(98)

(30)

Earnings before provision for taxes on income - as adjusted

$ 3,909

4,115

(5.0)

%

$ 19,169

18,214

5.2

%

Net Earnings attributable to Johnson & Johnson - as reported

$ 3,519

2,567

37.1

%

$ 13,831

10,853

27.4

%

Litigation expenses

227

371

1,646

1,052

In-process research and development

294

59

462

743

(1)

Synthes integration/transaction costs and currency related

110

306

483

899

DePuy ASR™ Hip program

118

73

240

97

Intangible asset write-downs

-

-

-

717

Scios Tax Benefit

(707)

-

(707)

-

Other

-

-

(79)

(16)

Net Earnings attributable to Johnson & Johnson - as adjusted 

$ 3,561

3,376

5.5

%

$ 15,876

14,345

10.7

%

Diluted Net Earnings per share attributable to Johnson & Johnson - as reported

$   1.23

0.91

35.2

%

$     4.81

3.86

24.6

%

Litigation expenses

0.08

0.13

0.57

0.37

In-process research and development

0.10

0.02

0.16

0.27

Synthes integration/transaction costs and currency related

0.04

0.11

0.17

0.32

DePuy ASR™ Hip program

0.04

0.02

0.08

0.03

Intangible asset write-downs

-

-

-

0.26

Scios Tax Benefit

(0.25)

-

(0.25)

-

Other

-

-

(0.02)

(0.01)

Diluted Net Earnings per share attributable to Johnson & Johnson - as adjusted 

$   1.24

1.19

4.2

%

$     5.52

5.10

8.2

%

(1) Amount includes third quarter in-process research and development charge of $679M related to bapineuzumab IV offset by $339M reported as net loss attributable to noncontrolling interest

The Company believes investors gain additional perspective of underlying business trends and results by providing a measure of earnings before provision for taxes on income, net earnings and diluted net earnings per share that excludes special items in order to evaluate ongoing business operations.

 

REPORTED SALES vs. PRIOR PERIOD ($MM)

FOURTH QUARTER

TWELVE MONTHS

% Change

% Change

2013

2012

Reported

Operational (1)

Currency

2013

2012

Reported

Operational (1)

Currency

CONSUMER SEGMENT (2) (4)

BABY CARE

US

$          105

103

1.9%

1.9%

-

$          413

412

0.2%

0.2%

-

Intl

480

469

2.3%

7.1%

-4.8%

1,882

1,842

2.2%

5.7%

-3.5%

WW

585

572

2.3%

6.2%

-3.9%

2,295

2,254

1.8%

4.7%

-2.9%

ORAL CARE

US

153

165

-7.3%

-7.3%

-

602

641

-6.1%

-6.1%

-

Intl

265

251

5.6%

8.6%

-3.0%

1,020

983

3.8%

5.9%

-2.1%

WW

418

416

0.5%

2.3%

-1.8%

1,622

1,624

-0.1%

1.1%

-1.2%

OTC (3)

US

332

273

21.6%

21.6%

-

1,286

1,074

19.7%

19.7%

-

Intl

747

743

0.5%

1.1%

-0.6%

2,742

2,692

1.9%

2.3%

-0.4%

WW

1,079

1,016

6.2%

6.6%

-0.4%

4,028

3,766

7.0%

7.3%

-0.3%

SKIN CARE

US

432

385

12.2%

12.2%

-

1,752

1,699

3.1%

3.1%

-

Intl

538

509

5.7%

7.4%

-1.7%

1,952

1,919

1.7%

2.6%

-0.9%

WW

970

894

8.5%

9.5%

-1.0%

3,704

3,618

2.4%

2.9%

-0.5%

WOMEN'S HEALTH

US

38

82

-53.7%

-53.7%

-

280

336

-16.7%

-16.7%

-

Intl

310

325

-4.6%

-0.8%

-3.8%

1,288

1,289

-0.1%

2.9%

-3.0%

WW

348

407

-14.5%

-11.5%

-3.0%

1,568

1,625

-3.5%

-1.1%

-2.4%

WOUND CARE/OTHER (3)

US

203

195

4.1%

4.1%

-

829

884

-6.2%

-6.2%

-

Intl

150

152

-1.3%

0.6%

-1.9%

651

676

-3.7%

-2.8%

-0.9%

WW

353

347

1.7%

2.6%

-0.9%

1,480

1,560

-5.1%

-4.7%

-0.4%

TOTAL CONSUMER

US

1,263

1,203

5.0%

5.0%

-

5,162

5,046

2.3%

2.3%

-

Intl

2,490

2,449

1.7%

4.1%

-2.4%

9,535

9,401

1.4%

3.1%

-1.7%

WW

$       3,753

3,652

2.8%

4.4%

-1.6%

$     14,697

14,447

1.7%

2.8%

-1.1%

See footnotes at end of schedule

 

REPORTED SALES vs. PRIOR PERIOD ($MM)

FOURTH QUARTER

TWELVE MONTHS

% Change

% Change

2013

2012

Reported

Operational (1)

Currency

2013

2012

Reported

Operational (1)

Currency

PHARMACEUTICAL SEGMENT (2) (4)

IMMUNOLOGY

US

$       1,726

1,448

19.2%

19.2%

-

$       6,591

5,972

10.4%

10.4%

-

Intl

676

528

28.0%

31.9%

-3.9%

2,599

1,902

36.6%

40.1%

-3.5%

WW

2,402

1,976

21.6%

22.6%

-1.0%

9,190

7,874

16.7%

17.5%

-0.8%

     REMICADE

     US 

982

871

12.7%

12.7%

-

3,891

3,583

8.6%

8.6%

-

     US Exports (5)

367

347

5.8%

5.8%

-

1,339

1,470

-8.9%

-8.9%

-

     Intl

363

286

26.9%

30.7%

-3.8%

1,443

1,086

32.9%

36.2%

-3.3%

     WW

1,712

1,504

13.8%

14.5%

-0.7%

6,673

6,139

8.7%

9.3%

-0.6%

     SIMPONI

     US

112

72

55.6%

55.6%

-

404

292

38.4%

38.4%

-

     Intl

142

109

30.3%

37.0%

-6.7%

528

315

67.6%

75.1%

-7.5%

     WW

254

181

40.3%

44.3%

-4.0%

932

607

53.5%

57.4%

-3.9%

     STELARA

     US

265

158

67.7%

67.7%

-

957

627

52.6%

52.6%

-

     Intl

152

111

36.9%

37.8%

-0.9%

547

398

37.4%

38.3%

-0.9%

     WW

417

269

55.0%

55.4%

-0.4%

1,504

1,025

46.7%

47.0%

-0.3%

     OTHER IMMUNOLOGY

     US

-

-

-

-

-

-

-

-

-

-

     Intl

19

22

-13.6%

-7.7%

-5.9%

81

103

-21.4%

-18.5%

-2.9%

     WW

19

22

-13.6%

-7.7%

-5.9%

81

103

-21.4%

-18.5%

-2.9%

INFECTIOUS DISEASES

US

302

236

28.0%

28.0%

-

1,077

974

10.6%

10.6%

-

Intl

642

620

3.5%

3.0%

0.5%

2,473

2,220

11.4%

11.5%

-0.1%

WW

944

856

10.3%

9.9%

0.4%

3,550

3,194

11.1%

11.1%

0.0%

     INCIVO

     US

-

-

-

-

-

-

-

-

-

-

     Intl

107

138

-22.5%

-23.6%

1.1%

517

443

16.7%

17.5%

-0.8%

     WW

107

138

-22.5%

-23.6%

1.1%

517

443

16.7%

17.5%

-0.8%

     INTELENCE

     US

49

46

6.5%

6.5%

-

187

176

6.3%

6.3%

-

     Intl

46

38

21.1%

20.2%

0.9%

192

173

11.0%

10.8%

0.2%

     WW

95

84

13.1%

12.7%

0.4%

379

349

8.6%

8.5%

0.1%

     PREZISTA

     US

229

165

38.8%

38.8%

-

807

672

20.1%

20.1%

-

     Intl

232

188

23.4%

22.8%

0.6%

866

742

16.7%

16.2%

0.5%

     WW

461

353

30.6%

30.3%

0.3%

1,673

1,414

18.3%

18.1%

0.2%

     OTHER INFECTIOUS DISEASES

     US

24

25

-4.0%

-4.0%

-

83

126

-34.1%

-34.1%

-

     Intl

257

256

0.4%

0.4%

0.0%

898

862

4.2%

4.4%

-0.2%

     WW

281

281

0.0%

0.0%

0.0%

981

988

-0.7%

-0.5%

-0.2%

 

REPORTED SALES vs. PRIOR PERIOD ($MM)

FOURTH QUARTER

TWELVE MONTHS

% Change

% Change

2013

2012

Reported

Operational (1)

Currency

2013

2012

Reported

Operational (1)

Currency

NEUROSCIENCE

US

611

601

1.7%

1.7%

-

2,584

2,611

-1.0%

-1.0%

-

Intl

1,040

1,088

-4.4%

0.1%

-4.5%

4,083

4,107

-0.6%

3.4%

-4.0%

WW

1,651

1,689

-2.2%

0.7%

-2.9%

6,667

6,718

-0.8%

1.6%

-2.4%

     CONCERTA/METHYLPHENIDATE

     US

46

116

-60.3%

-60.3%

-

308

609

-49.4%

-49.4%

-

     Intl

123

127

-3.1%

0.7%

-3.8%

474

464

2.2%

5.0%

-2.8%

     WW

169

243

-30.5%

-28.5%

-2.0%

782

1,073

-27.1%

-25.9%

-1.2%

     INVEGA

     US

87

76

14.5%

14.5%

-

316

299

5.7%

5.7%

-

     Intl

67

71

-5.6%

0.8%

-6.4%

267

251

6.4%

12.3%

-5.9%

     WW

154

147

4.8%

7.9%

-3.1%

583

550

6.0%

8.7%

-2.7%

     INVEGA SUSTENNA/ XEPLION

     US

188

132

42.4%

42.4%

-

690

482

43.2%

43.2%

-

     Intl

162

96

68.8%

69.4%

-0.6%

558

314

77.7%

76.8%

0.9%

     WW

350

228

53.5%

53.7%

-0.2%

1,248

796

56.8%

56.4%

0.4%

     RISPERDAL CONSTA

     US

113

103

9.7%

9.7%

-

440

439

0.2%

0.2%

-

     Intl

208

255

-18.4%

-16.0%

-2.4%

878

986

-11.0%

-8.7%

-2.3%

     WW

321

358

-10.3%

-8.6%

-1.7%

1,318

1,425

-7.5%

-5.9%

-1.6%

     OTHER NEUROSCIENCE

     US

177

174

1.7%

1.7%

-

830

782

6.1%

6.1%

-

     Intl

480

539

-10.9%

-4.8%

-6.1%

1,906

2,092

-8.9%

-3.3%

-5.6%

     WW

657

713

-7.9%

-3.3%

-4.6%

2,736

2,874

-4.8%

-0.7%

-4.1%

ONCOLOGY

US

216

135

60.0%

60.0%

-

848

506

67.6%

67.6%

-

Intl

897

684

31.1%

32.9%

-1.8%

2,925

2,123

37.8%

39.7%

-1.9%

WW

1,113

819

35.9%

37.4%

-1.5%

3,773

2,629

43.5%

45.0%

-1.5%

     VELCADE

     US

-

-

-

-

-

-

-

-

-

-

     Intl

524

502

4.4%

7.4%

-3.0%

1,660

1,500

10.7%

13.6%

-2.9%

     WW

524

502

4.4%

7.4%

-3.0%

1,660

1,500

10.7%

13.6%

-2.9%

     ZYTIGA

     US

211

114

85.1%

85.1%

-

750

463

62.0%

62.0%

-

     Intl

284

150

89.3%

86.5%

2.8%

948

498

90.4%

88.4%

2.0%

     WW

495

264

87.5%

85.9%

1.6%

1,698

961

76.7%

75.6%

1.1%

     OTHER ONCOLOGY

     US

5

21

-76.2%

-76.2%

-

98

43

*

*

-

     Intl

89

32

*

*

-1.8%

317

125

*

*

-2.2%

     WW

94

53

77.4%

79.1%

-1.7%

415

168

*

*

-1.7%

 

REPORTED SALES vs. PRIOR PERIOD ($MM)

FOURTH QUARTER

TWELVE MONTHS

% Change

% Change

2013

2012

Reported

Operational (1)

Currency

2013

2012

Reported

Operational (1)

Currency

TOTAL OTHER

US

696

593

17.4%

17.4%

-

2,848

2,358

20.8%

20.8%

-

Intl

490

592

-17.2%

-16.4%

-0.8%

2,097

2,578

-18.7%

-18.2%

-0.5%

WW

1,186

1,185

0.1%

0.5%

-0.4%

4,945

4,936

0.2%

0.5%

-0.3%

     ACIPHEX/PARIET

     US

(24)

92

*

*

-

265

372

-28.8%

-28.8%

-

     Intl

53

94

-43.6%

-43.1%

-0.5%

205

463

-55.7%

-55.5%

-0.2%

     WW

29

186

-84.4%

-84.2%

-0.2%

470

835

-43.7%

-43.6%

-0.1%

     PROCRIT/EPREX

     US

168

171

-1.8%

-1.8%

-

795

805

-1.2%

-1.2%

-

     Intl

139

155

-10.3%

-10.7%

0.4%

569

657

-13.4%

-14.0%

0.6%

     WW

307

326

-5.8%

-6.0%

0.2%

1,364

1,462

-6.7%

-7.0%

0.3%

     XARELTO

     US

271

95

*

*

-

864

239

*

*

-

     Intl

-

-

-

-

-

-

-

-

-

-

     WW

271

95

*

*

-

864

239

*

*

-

     OTHER

     US

281

235

19.6%

19.6%

-

924

942

-1.9%

-1.9%

-

     Intl

298

343

-13.1%

-11.6%

-1.5%

1,323

1,458

-9.3%

-8.2%

-1.1%

     WW

579

578

0.2%

1.1%

-0.9%

2,247

2,400

-6.4%

-5.8%

-0.6%

TOTAL PHARMACEUTICAL

US

3,551

3,013

17.9%

17.9%

-

13,948

12,421

12.3%

12.3%

-

Intl

3,745

3,512

6.6%

9.0%

-2.4%

14,177

12,930

9.6%

11.8%

-2.2%

WW

$       7,296

6,525

11.8%

13.1%

-1.3%

$     28,125

25,351

10.9%

12.0%

-1.1%

See footnotes at end of schedule.

 

REPORTED SALES vs. PRIOR PERIOD ($MM)

FOURTH QUARTER

TWELVE MONTHS

% Change

% Change

2013

2012

Reported

Operational (1)

Currency

2013

2012

Reported

Operational (1)

Currency

MEDICAL DEVICES AND DIAGNOSTICS (2)

CARDIOVASCULAR CARE

US

$          210

186

12.9%

12.9%

-

$          808

752

7.4%

7.4%

-

Intl

324

320

1.3%

5.7%

-4.4%

1,269

1,233

2.9%

7.0%

-4.1%

WW

534

506

5.5%

8.3%

-2.8%

2,077

1,985

4.6%

7.2%

-2.6%

DIABETES CARE

US

219

295

-25.8%

-25.8%

-

998

1,312

-23.9%

-23.9%

-

Intl

344

349

-1.4%

0.2%

-1.6%

1,311

1,304

0.5%

1.6%

-1.1%

WW

563

644

-12.6%

-11.9%

-0.7%

2,309

2,616

-11.7%

-11.2%

-0.5%

DIAGNOSTICS

US

215

258

-16.7%

-16.7%

-

926

1,025

-9.7%

-9.7%

-

Intl

251

272

-7.7%

-2.5%

-5.2%

959

1,044

-8.1%

-3.6%

-4.5%

WW

466

530

-12.1%

-9.4%

-2.7%

1,885

2,069

-8.9%

-6.6%

-2.3%

INFECTION PREVENTION/OTHER

US

90

86

4.7%

4.7%

-

361

399

-9.5%

-9.5%

-

Intl

156

160

-2.5%

5.2%

-7.7%

551

553

-0.4%

6.4%

-6.8%

WW

246

246

0.0%

5.0%

-5.0%

912

952

-4.2%

-0.3%

-3.9%

ORTHOPAEDICS

US 

1,307

1,246

4.9%

4.9%

-

5,074

4,144

22.4%

22.4%

-

Intl

1,149

1,142

0.6%

3.5%

-2.9%

4,435

3,655

21.3%

24.6%

-3.3%

WW

2,456

2,388

2.8%

4.2%

-1.4%

9,509

7,799

21.9%

23.4%

-1.5%

SPECIALTY SURGERY

US

332

326

1.8%

1.8%

-

1,303

1,297

0.5%

0.5%

-

Intl

351

329

6.7%

10.7%

-4.0%

1,289

1,229

4.9%

8.1%

-3.2%

WW

683

655

4.3%

6.3%

-2.0%

2,592

2,526

2.6%

4.2%

-1.6%

SURGICAL CARE 

US

599

618

-3.1%

-3.1%

-

2,294

2,415

-5.0%

-5.0%

-

Intl

1,040

1,049

-0.9%

3.4%

-4.3%

3,975

4,068

-2.3%

1.3%

-3.6%

WW

1,639

1,667

-1.7%

1.0%

-2.7%

6,269

6,483

-3.3%

-1.0%

-2.3%

VISION CARE

US

228

229

-0.4%

-0.4%

-

1,036

1,019

1.7%

1.7%

-

Intl

491

516

-4.8%

4.0%

-8.8%

1,901

1,977

-3.8%

4.3%

-8.1%

WW

719

745

-3.5%

2.6%

-6.1%

2,937

2,996

-2.0%

3.3%

-5.3%

TOTAL MEDICAL DEVICES AND DIAGNOSTICS

US

3,200

3,244

-1.4%

-1.4%

-

12,800

12,363

3.5%

3.5%

-

Intl

4,106

4,137

-0.7%

3.7%

-4.4%

15,690

15,063

4.2%

8.3%

-4.1%

WW

$       7,306

7,381

-1.0%

1.5%

-2.5%

$     28,490

27,426

3.9%

6.1%

-2.2%

* Percentage greater than 100%

(1) Operational growth excludes the effect of currency

(2) Unaudited

(3) Nutritionals now reflected in Wound Care/Other, previously reported in OTC/Nutritionals

(4) Prior year amounts have been reclassified to conform to current year product disclosure

(5) Reported as U.S. sales

SOURCE Johnson & Johnson



RELATED LINKS

http://www.jnj.com